Zinner Named CEO of Miami Cancer Institute

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MICHAEL ZINNER was named CEO and executive medical director of Miami Cancer Institute at Baptist Health South Florida.

Zinner served as clinical director at Dana-Farber/Brigham and Women’s Cancer Center, and surgeon-in-chief at the Brigham and Women’s Hospital. He is also the Moseley Professor of Surgery at Harvard Medical School and founder of Harvard’s Center for Surgery and Public Health. Zinner is also co-founder and co-director of the Gastrointestinal Cancer Center at Dana-Farber Cancer Institute.

From 2008 to 2010, Zinner was the chairman of the Board of Governors of the American College of Surgeons, and is now vice chair of the Board of Regents. Additionally, he is chairman of the organization’s Health Policy and Advocacy Committee.

A Miami native, Dr. Zinner received his M.D. degree from the University of Florida and did his surgical residency at Johns Hopkins Hospital.

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login